688131 皓元医药
2024/06 - 中期2023/122022/122021/122020/12

盈利能力分析
净资产收益率 ROE (%)2.7455.2789.35016.25327.693
总资产报酬率 ROA (%)1.6443.2726.47411.78418.356
投入资产回报率 ROIC (%)1.8643.7857.55513.86322.771

边际利润分析
销售毛利率 (%)45.37545.16851.44454.11856.674
营业利润率 (%)7.4356.82614.47421.64123.412
息税前利润/营业总收入 (%)8.7368.51314.57722.26124.787
净利润/营业总收入 (%)6.5296.71814.10519.66220.223

收益指标分析
经营活动净收益/利润总额(%)173.176161.741107.449109.025113.942
价值变动净收益/利润总额(%)-6.670-3.7238.085-0.0570.978
营业外收支净额/利润总额(%)0.209-0.1060.995-0.111-0.051

偿债能力分析
流动比率 (X)1.9601.8802.2174.9442.160
速动比率 (X)0.9910.8961.1093.8491.384
资产负债率 (%)39.55839.73935.18322.98638.401
带息债务/全部投入资本 (%)24.64324.23215.3670.69518.809
股东权益/带息债务 (%)273.965282.011492.78912,717.344405.343
股东权益/负债合计 (%)151.538150.611183.280332.471160.412
利息保障倍数 (X)6.7935.025-342.76634.56917.871

营运能力分析
应收账款周转天数 (天)85.89075.32063.74341.66837.542
存货周转天数 (天)350.758359.057344.748235.069247.717